Monica Lupi

List of Publications by Year
in descending order

62 papers	**1,570** citations	304368 **22** h-index	344852 **36** g-index
63 all docs	**63** docs citations	**63** times ranked	**2762** citing authors

#	Article	IF	Citations
1	Role of cardiolipins, mitochondria, and autophagy in the differentiation process activated by all-trans retinoic acid in acute promyelocytic leukemia. Cell Death and Disease, 2022, 13, 30.	2.7	3
2	PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer. Cancer Research, 2022, 82, 1423-1434.	0.4	14
3	Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells. Cancers, 2022, 14, 1807.	1.7	10
4	Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study. International Journal of Molecular Sciences, 2022, 23, 5786.	1.8	9
5	Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations. Cell Death and Disease, 2022, 13, .	2.7	2
6	Preformed Biodegradable Zwitterionic Nanoparticles as Tunable Excipients for the Formulation of Therapeutics Directly at the Point of Care. Industrial & Engineering Chemistry Research, 2021, 60, 10699-10709.	1.8	6
7	Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation. Cells, 2020, 9, 1766.	1.8	19
8	Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma. Cancers, 2020, 12, 672.	1.7	20
9	All-Trans Retinoic Acid Stimulates Viral Mimicry, Interferon Responses and Antigen Presentation in Breast-Cancer Cells. Cancers, 2020, 12, 1169.	1.7	15
10	Role of mitochondria and cardiolipins in growth inhibition of breast cancer cells by retinoic acid. Journal of Experimental and Clinical Cancer Research, 2019, 38, 436.	3.5	11
11	DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas. Molecular Cancer Therapeutics, 2019, 18, 1255-1264.	1.9	27
12	S100A3 a partner protein regulating the stability/activity of RARα and PML-RARα in cellular models of breast/lung cancer and acute myeloid leukemia. Oncogene, 2019, 38, 2482-2500.	2.6	18
13	ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells. Haematologica, 2019, 104, 533-545.	1.7	21
14	Synthesis and characterization of pH-sensitive drinkable nanoparticles for oral delivery of ibuprofen. Nanotechnology, 2018, 29, 225604.	1.3	14
15	Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines. Targeted Oncology, 2018, 13, 235-245.	1.7	8
16	Self‐Assembling PCL‐Based Nanoparticles as PTX Solubility Enhancer Excipients. Macromolecular Bioscience, 2018, 18, e1800164.	2.1	9
17	In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models. Neoplasia, 2017, 19, 35-42.	2.3	21
18	Poly(HPMA)-based copolymers with biodegradable side chains able to self assemble into nanoparticles. RSC Advances, 2017, 7, 50981-50992.	1.7	24

#	Article	IF	Citations
19	Small interfering RNA delivery through positively charged polymer nanoparticles. Nanotechnology, 2016, 27, 125102.	1.3	10
20	Magnetic domain wall tweezers: a new tool for mechanobiology studies on individual target cells. Lab on A Chip, 2016, 16, 2882-2890.	3.1	12
21	PEGylated Nanoparticles Obtained through Emulsion Polymerization as Paclitaxel Carriers. Molecular Pharmaceutics, 2016, 13, 40-46.	2.3	31
22	Fate of PLA and PCL-Based Polymeric Nanocarriers in Cellular and Animal Models of Triple-Negative Breast Cancer. Biomacromolecules, 2016, 17, 744-755.	2.6	19
23	Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer. Oncotarget, 2016, 7, 15492-15506.	0.8	8
24	Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS. Oncotarget, 2016, 7, 51462-51472.	0.8	21
25	Cellular and molecular determinants of all‑*trans* retinoic acid sensitivity in breast cancer: *Luminal* phenotype and RARα expression. EMBO Molecular Medicine, 2015, 7, 950-972.	3.3	60
26	Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. Oncotarget, 2015, 6, 3394-3408.	0.8	56
27	MicroRNA networks regulated by *all-trans* retinoic acid and Lapatinib control the growth, survival and motility of breast cancer cells. Oncotarget, 2015, 6, 13176-13200.	0.8	33
28	Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2. Oncotarget, 2015, 6, 28389-28400.	0.8	13
29	Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells. Oncotarget, 2015, 6, 30072-30087.	0.8	43
30	Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736. Oncotarget, 2015, 6, 37229-37240.	0.8	21
31	A biodistribution study of PEGylated PCL-based nanoparticles in C57BL/6 mice bearing B16/F10 melanoma. Nanotechnology, 2014, 25, 335706.	1.3	22
32	Investigation of size, surface charge, PEGylation degree and concentration on the cellular uptake of polymer nanoparticles. Colloids and Surfaces B: Biointerfaces, 2014, 123, 639-647.	2.5	50
33	Integrated multiplatform method for *in vitro* quantitative assessment of cellular uptake for fluorescent polymer nanoparticles. Nanotechnology, 2014, 25, 045102.	1.3	19
34	Benzylidenetetralones, cyclic chalcone analogues, induce cell cycle arrest and apoptosis in HCT116 colorectal cancer cells. Tumor Biology, 2014, 35, 9967-9975.	0.8	27
35	Synthesis of surfactant free PCL–PEG brushed nanoparticles with tunable degradation kinetics. International Journal of Pharmaceutics, 2013, 453, 551-559.	2.6	45
36	Cytotoxicity of PMMA‑Based Nanoparticles Synthesized Adopting SDS and Tween 80. Macromolecular Symposia, 2013, 324, 134-139.	0.4	12

#	Article	IF	Citations
37	Chk1-Mad2 interaction. Cell Cycle, 2013, 12, 1083-1090.	1.3	38
38	Biocompatible fluorescent nanoparticles for *in vivo* stem cell tracking. Nanotechnology, 2013, 24, 245603.	1.3	29
39	An opto-structural method to estimate the stress-strain field induced by cell contraction on substrates of controlled stiffness in vitro. Journal of Applied Biomaterials and Functional Materials, 2013, 11, 143-150.	0.7	2
40	Dynamic Rendering of the Heterogeneous Cell Response to Anticancer Treatments. PLoS Computational Biology, 2013, 9, e1003293.	1.5	12
41	A Methyl Methacrylate–<scp>HEMA</scp>–<scp>CL</scp>_{*n*} Copolymerization Investigation: From Kinetics to Bioapplications. Macromolecular Bioscience, 2013, 13, 1347-1357.	2.1	10
42	Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle, 2012, 11, 2507-2517.	1.3	110
43	Human Axonal Survival of Motor Neuron (a-SMN) Protein Stimulates Axon Growth, Cell Motility, C-C Motif Ligand 2 (CCL2), and Insulin-like Growth Factor-1 (IGF1) Production. Journal of Biological Chemistry, 2012, 287, 25782-25794.	1.6	26
44	Challenges in the Integration of Flow Cytometry and Time-Lapse Live Cell Imaging Data Using a Cell Proliferation Model. SIMAI Springer Series, 2012, , 376-398.	0.4	2
45	The Molecular Assembly of Amyloid Aβ Controls Its Neurotoxicity and Binding to Cellular Proteins. PLoS ONE, 2011, 6, e24909.	1.1	39
46	Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells. Cancer Chemotherapy and Pharmacology, 2011, 67, 369-379.	1.1	48
47	Interoperability of time series cytometric data: A cross platform approach for modeling tumor heterogeneity. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2011, 79A, 214-226.	1.1	11
48	Induction of miR-21 by Retinoic Acid in Estrogen Receptor-positive Breast Carcinoma Cells. Journal of Biological Chemistry, 2011, 286, 4027-4042.	1.6	82
49	Quantitative Assessment of the Complex Dynamics of G1, S, and G2-M Checkpoint Activities. Cancer Research, 2009, 69, 5234-5240.	0.4	25
50	The Contribution of p53 in the Dynamics of Cell Cycle Response to DNA Damage Interpreted by a Mathematical Model. Cell Cycle, 2007, 6, 943-950.	1.3	20
51	Antiproliferative Activity of Cisplatin Detected by CFSE in p53-Proficient and p53-Deficient Cells. Immunological Investigations, 2007, 36, 847-859.	1.0	3
52	Neurodegeneration induced by complex I inhibition in a cellular model of familial amyotrophic lateral sclerosis. Brain Research Bulletin, 2006, 69, 465-474.	1.4	23
53	Interpreting cell cycle effects of drugs: the case of melphalan. Cancer Chemotherapy and Pharmacology, 2006, 57, 443-457.	1.1	23
54	Tetracycline-regulated gene expression in the NSC-34-tTA cell line for investigation of motor neuron diseases. Molecular Brain Research, 2005, 140, 63-72.	2.5	11

#	Article	IF	Citations
55	Low levels of ALS-linked Cu/Zn superoxide dismutase increase the production of reactive oxygen species and cause mitochondrial damage and death in motor neuron-like cells. Journal of the Neurological Sciences, 2005, 232, 95-103.	0.3	68
56	Heterogeneous cell response to topotecan in a CFSE-based proliferation test. Cytometry, 2004, 62A, 118-128.	1.8	30
57	Cytostatic and Cytotoxic Effects of Topotecan Decoded by a Novel Mathematical Simulation Approach. Cancer Research, 2004, 64, 2825-2832.	0.4	30
58	Mitochondrial dysfunction and death in motor neurons exposed to the glutathione-depleting agent ethacrynic acid. Journal of the Neurological Sciences, 2003, 207, 51-58.	0.3	81
59	Timing the changes of cyclin E cell content in G1 in exponentially growing cells. Experimental Cell Research, 2003, 288, 158-167.	1.2	9
60	Variability in the timing of G1/S transition. Mathematical Biosciences, 2002, 177-178, 85-101.	0.9	6
61	Solar UV radiation: differential effectiveness of UVB subcomponents in causing cell death, micronucleus induction and delayed expression of heritable damage in human hybrid cells. International Journal of Radiation Biology, 2001, 77, 963-970.	1.0	5
62	Cell cycle effects of gemcitabine. International Journal of Cancer, 2001, 93, 401-408.	2.3	73